FDA Approves First AI Tool AIM-NASH to Advance Liver Disease Trials
The U.S. Food and Drug Administration has reached a groundbreaking regulatory milestone by officially qualifying AIM-NASH as the world’s first AI-based drug development tool for assessing metabolic dysfunction-associated steatohepatitis (MASH), a severe and progressive type of fatty liver disease. This qualification marks one of the significant milestones in the integration of artificial intelligence into clinical … Read more